Aldehyde Dehydrogenase 2 in Cardiac Protection: A New Therapeutic Target?☆
Abstract
Mitochondrial aldehyde dehydrogenase 2 (ALDH2) is emerging as a key enzyme involved in cytoprotection in the heart. ALDH2 mediates both the detoxification of reactive aldehydes such as acetaldehyde and 4-hydroxy-2-nonenal and the bioactivation of nitroglycerin to nitric oxide. In addition, chronic nitrate treatment results in ALDH2 inhibition and contributes to nitrate tolerance. Our laboratory recently identified ALDH2 to be a key mediator of endogenous cytoprotection. We reported that ALDH2 is phosphorylated and activated by the survival kinase protein kinase C ɛ and found a strong inverse correlation between ALDH2 activity and infarct size. We also identified a small molecule ALDH2 activator which reduces myocardial infarct size induced by ischemia/reperfusion in vivo. In this review, we discuss evidence that ALDH2 is a key mediator of endogenous survival signaling in the heart, suggest possible cardioprotective mechanisms mediated by ALDH2 and discuss potential clinical implications of these findings.
To access this article, please choose from the options below
☆ This work was supported by NIAA11147 to DMR and in part, by an American Heart Association postdoctoral fellowship to GRB.
PII: S1050-1738(09)00145-5
doi:10.1016/j.tcm.2009.09.003
© 2009 Elsevier Inc. All rights reserved.
